Topiramate (Epilepsy)

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8144
R25035
Cohen (Topiramate) (Controls exposed to Lamotrigine, sick), 2019 Preterm birth (ICD-9 644.2, 774.2, 776.6, 362.20, 362.22, 362.27, 765 excluding 765.20, 765.29) early pregnancy retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 0.94 [0.57;1.55]
excluded (control group)
-/-   -/- - -
ref
S8140
R25007
Cohen (Topiramate) (Controls unexposed NOS), 2019 Preterm birth (ICD-9 644.2, 774.2, 776.6, 362.20, 362.22, 362.27, 765 excluding 765.20, 765.29) early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 0.74 [0.48;1.16] -/-   160,604/1,440,631 160,595 -
ref
S6251
R16642
Arkilo (Topiramate), 2015 Premature delivery during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No 1.95 [0.07;58.24] C 0/2   3/24 3 2
ref
Total 2 studies 0.75 [0.49;1.16] 160,598 2
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Cohen (Topiramate) (Controls unexposed NOS), 2019Cohen, 2019 1 0.74[0.48; 1.16]160,595-98%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Arkilo (Topiramate), 2015Arkilo, 2015 2 1.95[0.07; 58.24]322%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 0.75[0.49; 1.16]160,59820.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Controls unexposed NOS; 2: Topiramate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.75[0.49; 1.16]160,59820%NACohen (Topiramate) (Controls unexposed NOS), 2019 Arkilo (Topiramate), 2015 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.74[0.48; 1.15]160,595- -NACohen (Topiramate) (Controls unexposed NOS), 2019 1 exposed to other treatment, sickexposed to other treatment, sick 1.95[0.07; 58.24]32 -NAArkilo (Topiramate), 2015 1 Tags Adjustment   - No  - No 1.95[0.07; 58.24]32 -NAArkilo (Topiramate), 2015 1   - Yes  - Yes 0.74[0.48; 1.15]160,595- -NACohen (Topiramate) (Controls unexposed NOS), 2019 1 All studiesAll studies 0.75[0.49; 1.16]160,59820%NACohen (Topiramate) (Controls unexposed NOS), 2019 Arkilo (Topiramate), 2015 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8144

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.74[0.48; 1.15]160,595- -NACohen (Topiramate) (Controls unexposed NOS), 2019 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.95[0.58; 1.57]320%NACohen (Topiramate) (Controls exposed to Lamotrigine, sick), 2019 Arkilo (Topiramate), 2015 20.510.01.0